OS Therapies Incorporated (OSTX)
OS Therapies Incorporated operates in the Biotechnology industry of the Healthcare sector, headquartered in Grasonville, MD, US. The stock last traded at $1.66, up 0.30% on the session, giving a market capitalisation of $75.6M. On trailing twelve-month figures it carries a trailing P/E of -1.52, a net margin of 0.0%. Its beta of -0.68 implies it has historically moved less than the broad market.
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
OS Therapies Incorporated is most often compared with the following Healthcare names: